Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    26,035 result(s) found. Displaying page 1,000 of 1,302.
    «« First « Previous 996  997  998  999  1000  1001  1002  1003  1004  Next» Last»»
    EudraCT Number: 2009-010669-22 Sponsor Protocol Number: 1237.6 Start Date*: 2011-09-19
    Sponsor Name: [...]
    1.
    2. Boehringer Ingelheim Norway KS
    Full Title: A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium plus olodaterol fixed dose combination (2.5 μg / ...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) ES (Completed) SK (Completed) BE (Completed) DE (Completed) HU (Completed) IE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000854-44 Sponsor Protocol Number: 170CDT01 Start Date*: 2011-05-02
    Sponsor Name:Toray Industries Inc
    Full Title: A Two Part, Multi Centre, Randomized, Placebo Controlled, Double Blind Study of TRK 170 for the Treatment of Crohn's Disease
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) NO (Completed) HU (Completed) NL (Completed) PL (Completed) CZ (Completed) BG (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-002066-20 Sponsor Protocol Number: 905-CL-076 Start Date*: 2012-11-01
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 3, Double-Blind, Randomized, Multi-center, Placebo-Controlled Sequential Dose Titration Study to Assess Efficacy, Safety and Population Pharmacokinetics of Solifenacin Succinate Suspension ...
    Medical condition: Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) NL (Completed) DE (Completed) SE (Completed) DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2010-021395-28 Sponsor Protocol Number: B3D-MC-GHDN Start Date*: 2012-04-03
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of Teriparatide on Femoral Neck Fracture Healing
    Medical condition: Low trauma femoral neck fracture
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10016450 Femoral neck fracture PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) LV (Completed) FI (Completed) NO (Completed) LT (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011360-10 Sponsor Protocol Number: CL3-16257-083 Start Date*: 2009-10-13
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efectos de ivabradina en pacientes con arteriopatía coronaria estable sin insuficiencia cardíaca clínica. Estudio multicéntrico, internacional, aleatorizado, doble ciego, controlado con placebo St...
    Medical condition: Arteriopatia Coronaria Estable Stable coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10011078 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) GB (Completed) NL (Completed) FI (Completed) LV (Completed) HU (Completed) CZ (Completed) SK (Completed) IE (Completed) BE (Completed) FR (Completed) LT (Completed) DE (Completed) AT (Completed) SE (Completed) IT (Completed) GR (Completed) EE (Completed) SI (Completed) BG (Completed) DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2011-003415-31 Sponsor Protocol Number: ARD12166 Start Date*: 2012-01-25
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: Randomized Phase II Study of Cabazitaxel versus Topotecan in Small Cell Lung Cancer Patients with Progressive Disease during or after a First Line Platinum Based Chemotherapy
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041071 Small cell lung cancer stage unspecified PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) GR (Completed) NO (Completed) IT (Completed) DE (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022897-14 Sponsor Protocol Number: PreMENAC-2011-01 Start Date*: 2011-05-02
    Sponsor Name:Dep. of Cancer Research and Molecular medicine, Norwegian University of Science and Technology
    Full Title: PreMENAC: Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia: A feasibility study (phase II)
    Medical condition: Diagnosis of non operable non-small cell lung cancer NSCLC (stage III-IV) or pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001180-53 Sponsor Protocol Number: TMC435HPC3001 Start Date*: 2012-01-06
    Sponsor Name:Janssen R&D Ireland
    Full Title: A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C gen...
    Medical condition: Hepatitis C Virus (HCV) genotype-1 infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GR (Completed) BE (Completed) ES (Completed) DE (Completed) SE (Completed) HU (Completed) AT (Completed) DK (Completed) PL (Completed) CZ (Completed) NO (Completed) GB (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-000073-23 Sponsor Protocol Number: CRAD001YIC04 Start Date*: 2012-05-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrin...
    Medical condition: Estrogen receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) NL (Completed) SE (Completed) NO (Completed) ES (Completed) DK (Completed) FI (Completed) BE (Completed) CZ (Prematurely Ended) IT (Completed) HU (Completed) IE (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-002047-10 Sponsor Protocol Number: 905-CL-077 Start Date*: 2012-11-01
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)
    Medical condition: Overactive Bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) NL (Completed) DE (Prematurely Ended) DK (Completed) SE (Completed) NO (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-003536-23 Sponsor Protocol Number: SFY13370 Start Date*: 2013-02-20
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intoleran...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) ES (Completed) IT (Completed) SE (Completed) EE (Completed) NO (Completed) FI (Completed) NL (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002806-59 Sponsor Protocol Number: LTS11717 Start Date*: 2012-02-10
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: Long-term safety and tolerability of REGN727 / SAR236553 in high cardiovascular risk patients with hypercholesterolemia not adequately controlled with their lipid modifying therapy: a randomized, d...
    Medical condition: Hypercholesterolaemia.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) SE (Completed) ES (Completed) PT (Completed) DE (Completed) CZ (Completed) NO (Completed) GB (Completed) NL (Completed) HU (Completed) IT (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-012852-26 Sponsor Protocol Number: EFC11319 Start Date*: 2010-09-06
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: Estudio multicéntrico doble ciego, aleatorizado, controlado con placebo y de grupos paralelos, para evaluar los eventos cardiovasculares durante el tratamiento con lixisenatide en pacientes con dia...
    Medical condition: Diabetes tipo II ___________________ Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed) GB (Completed) LT (Completed) EE (Completed) DK (Completed) LV (Completed) IT (Completed) NL (Completed) SE (Completed) FR (Completed) FI (Completed) BG (Completed) BE (Completed) NO (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001984-66 Sponsor Protocol Number: EFC11574 Start Date*: 2013-04-25
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment with Adal...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    15.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) CZ (Completed) ES (Completed) GR (Completed) LT (Prematurely Ended) FI (Completed) LV (Prematurely Ended) IT (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2012-003292-19 Sponsor Protocol Number: EFC12703 Start Date*: 2013-06-04
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter, 24 week study assessing the safety and efficacy of lixisenatide in older patients with type 2 diabetes inadequatel...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) ES (Completed) NO (Completed) DE (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-002343-29 Sponsor Protocol Number: R727-CL-1308 Start Date*: 2013-10-21
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia
    Medical condition: Primary Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) SK (Completed) BG (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2012-002270-31 Sponsor Protocol Number: 1275.9 Start Date*: 2012-12-19
    Sponsor Name:Boehringer Ingelheim España, S.A
    Full Title: A phase III, randomised, double-blind, parallel group, 24 week study to evaluate efficacy and safety of once daily empagliflozin 10 mg and 25 mg compared to placebo, all administered as oral fixed ...
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NO (Completed) IT (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019318-26 Sponsor Protocol Number: IMCL_CP12-0919_(I4T-IE-JVBF) Start Date*: 2010-09-27
    Sponsor Name:ImClone LLC
    Full Title: A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepato...
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) CZ (Completed) PT (Completed) BE (Completed) ES (Completed) AT (Completed) FR (Completed) BG (Completed) HU (Completed) IT (Completed) SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2012-003580-21 Sponsor Protocol Number: NN9211-3919 Start Date*: 2013-05-14
    Sponsor Name:Novo Nordisk A/S
    Full Title: The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallelgroup,...
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) IE (Completed) NL (Completed) GB (Completed) NO (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016244-39 Sponsor Protocol Number: 1245.28 Start Date*: 2010-10-18
    Sponsor Name:Boehringer Ingelheim B.V.
    Full Title: A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks in patients with type 2 dia...
    Medical condition: Type 2 diabetes mellitus pre-treated with metformin
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) NO (Completed) FI (Completed) SE (Completed) IT (Completed) ES (Completed) GB (Completed) PT (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 996  997  998  999  1000  1001  1002  1003  1004  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Feb 16 23:44:58 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA